Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Researchers have used artificial intelligence to identify 25 new protein compounds that can kill bacteria and fungi, ...